Home › Colorectal Cancer › Connecticut
Colorectal Cancer clinical trials in Connecticut
23 studies for Colorectal Cancer are looking for participants at sites in Connecticut.
Cities in Connecticut
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
- Yale University School of Medicine /ID# 279373, New Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07525206The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Yale Cancer Center, New Haven
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #62, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Yale University School of Medicine, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06324357A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- Yale Cancer Center, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07578571A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
- Yale New Haven Hospital /ID# 270565, New Haven
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06820463A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Yale University School Of Medicine, New Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06662786A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
- Kivu Trial Site, New Have
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07229313Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Yale-New Haven Hospital-Yale Cancer Center, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06445062Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Yale Cancer Center, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07349537Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Yale University School of Medicine - Yale Cancer Center, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT05786924A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- Hartford Hospital, Hartford
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07284849A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- Yale Cancer Center, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT04929223Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
- Clinical Study Site, Hartford
- Clinical Study Site, New Haven
- Clinical Study Site, Norwich
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT07228832A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
- Yale University, New Haven
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT06992258FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Yale University School of Medicine, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05919264Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
- Eastern Connecticut Hematology and Oncology Associates, Norwich
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT07397338Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
- Yale University, New Haven
- Smilow Cancer Hospital Care Center-Trumbull, Trumbull
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT05691491A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
- Yale Comprehensive Cancer Center, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT07169734A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
- Yale University, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT07079631Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Smilow Cancer Hospital (Yale University), New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 3, 2026 · NCT06040541BBO-11818 in Adult Subjects With KRAS Mutant Cancer
- Yale University, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 2, 2026 · NCT06917079A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Yale University, Yale Cancer Center, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 27, 2026 · NCT06395519From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.